Real-world Evaluation of Early Remdesivir in High-risk COVID-19 Outpatients During Omicron Including BQ.1/BQ.1.1/XBB.1.5

Overview

Journal BMC Infect Dis

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Aug 8

PMID 39118052

Authors

Kyle C Molina

Brandon J Webb

Victoria Kennerley

Laurel E Beaty

Tellen D Bennett

Nichole E Carlson

David A Mayer

Jennifer L Peers

Seth Russell

Matthew K Wynia

Neil R Aggarwal

Adit A Ginde

Affiliations

Soon will be listed here.

Abstract

Background: A trial performed among unvaccinated, high-risk outpatients with COVID-19 during the delta period showed remdesivir reduced hospitalization. We used our real-world data platform to determine the effectiveness of remdesivir on reducing 28-day hospitalization among outpatients with mild-moderate COVID-19 during an Omicron period including BQ.1/BQ.1.1/XBB.1.5.

Methods: We did a propensity-matched, retrospective cohort study of non-hospitalized adults with SARS-CoV-2 infection between April 7, 2022, and February 7, 2023. Electronic healthcare record data from a large health system in Colorado were linked to statewide vaccination and mortality data. We included patients with a positive SARS-CoV-2 test or outpatient remdesivir administration. Exclusion criteria were other SARS-CoV-2 treatments or positive SARS-CoV-2 test more than seven days before remdesivir. The primary outcome was all-cause hospitalization up to day 28. Secondary outcomes included 28-day COVID-related hospitalization and 28-day all-cause mortality.

Results: Among 29,270 patients with SARS-CoV-2 infection, 1,252 remdesivir-treated patients were matched to 2,499 untreated patients. Remdesivir was associated with lower 28-day all-cause hospitalization (1.3% vs. 3.3%, adjusted hazard ratio (aHR) 0.39 [95% CI 0.23-0.67], p < 0.001) than no treatment. All-cause mortality at 28 days was numerically lower among remdesivir-treated patients (0.1% vs. 0.4%; aOR 0.32 [95% CI 0.03-1.40]). Similar benefit of RDV treatment on 28-day all-cause hospitalization was observed across Omicron periods, aOR (95% CI): BA.2/BA2.12.1 (0.77[0.19-2.41]), BA.4/5 (0.50[95% CI 0.50-1.01]), BQ.1/BQ.1.1/XBB.1.5 (0.21[95% CI 0.08-0.57].

Conclusion: Among outpatients with SARS-CoV-2 during recent Omicron surges, remdesivir was associated with lower hospitalization than no treatment, supporting current National Institutes of Health Guidelines.

References

Focosi D, McConnell S, Casadevall A, Cappello E, Valdiserra G, Tuccori M . Monoclonal antibody therapies against SARS-CoV-2. Lancet Infect Dis. 2022; 22(11):e311-e326. PMC: 9255948. DOI: 10.1016/S1473-3099(22)00311-5. View

Lim S, Tignanelli C, Hoertel N, Boulware D, Usher M . Prevalence of Medical Contraindications to Nirmatrelvir/Ritonavir in a Cohort of Hospitalized and Nonhospitalized Patients With COVID-19. Open Forum Infect Dis. 2022; 9(8):ofac389. PMC: 9384640. DOI: 10.1093/ofid/ofac389. View

Heinze G, Schemper M . A solution to the problem of separation in logistic regression. Stat Med. 2002; 21(16):2409-19. DOI: 10.1002/sim.1047. View

Cao Z, Gao W, Bao H, Feng H, Mei S, Chen P . VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19. N Engl J Med. 2022; 388(5):406-417. PMC: 9812289. DOI: 10.1056/NEJMoa2208822. View

Piccicacco N, Zeitler K, Ing A, Montero J, Faughn J, Silbert S . Real-world effectiveness of early remdesivir and sotrovimab in the highest-risk COVID-19 outpatients during the Omicron surge. J Antimicrob Chemother. 2022; 77(10):2693-2700. PMC: 9384598. DOI: 10.1093/jac/dkac256. View

Chesdachai S, Rivera C, Cole K, Teaford H, Gonzalez Suarez M, Larsen J . Comparable outcomes of outpatient remdesivir and sotrovimab among high-risk patients with mild to moderate COVID-19 during the omicron BA.1 surge. Sci Rep. 2024; 14(1):5430. PMC: 10914739. DOI: 10.1038/s41598-024-56195-y. View

Rajme-Lopez S, Martinez-Guerra B, Roman-Montes C, Tamez-Torres K, Tello-Mercado A, Tepo-Ponce K . Nirmatrelvir/ritonavir and remdesivir against symptomatic treatment in high-risk COVID-19 outpatients to prevent hospitalization or death during the Omicron era: a propensity score-matched study. Ther Adv Infect Dis. 2024; 11:20499361241236582. PMC: 10966993. DOI: 10.1177/20499361241236582. View

Puhr R, Heinze G, Nold M, Lusa L, Geroldinger A . Firth's logistic regression with rare events: accurate effect estimates and predictions?. Stat Med. 2017; 36(14):2302-2317. DOI: 10.1002/sim.7273. View

Nguyen T, Collins G, Spence J, Daures J, Devereaux P, Landais P . Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017; 17(1):78. PMC: 5408373. DOI: 10.1186/s12874-017-0338-0. View

10.

Beigel J, Tomashek K, Dodd L, Mehta A, Zingman B, Kalil A . Remdesivir for the Treatment of Covid-19 - Final Report. N Engl J Med. 2020; 383(19):1813-1826. PMC: 7262788. DOI: 10.1056/NEJMoa2007764. View

11.

Aggarwal N, Molina K, Beaty L, Bennett T, Carlson N, Mayer D . Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023; 23(6):696-705. PMC: 10014040. DOI: 10.1016/S1473-3099(23)00011-7. View

12.

Austin P . Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2010; 10(2):150-61. PMC: 3120982. DOI: 10.1002/pst.433. View

13.

Wynia M, Beaty L, Bennett T, Carlson N, Davis C, Kwan B . Real-World Evidence of Neutralizing Monoclonal Antibodies for Preventing Hospitalization and Mortality in COVID-19 Outpatients. Chest. 2022; 163(5):1061-1070. PMC: 9613796. DOI: 10.1016/j.chest.2022.10.020. View

14.

Gottlieb R, Vaca C, Paredes R, Mera J, Webb B, Perez G . Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. N Engl J Med. 2021; 386(4):305-315. PMC: 8757570. DOI: 10.1056/NEJMoa2116846. View

15.

Butler C, Hobbs F, Gbinigie O, Rahman N, Hayward G, Richards D . Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial. Lancet. 2022; 401(10373):281-293. PMC: 9779781. DOI: 10.1016/S0140-6736(22)02597-1. View